The protective effect of hepatic dysfunction on vascularized allograft survival

Patrick Roughneen, R. Didlake, S. C. Kumar, B. D. Kahan, B. J. Rowlands

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recent studies have demonstrated that hepatic dysfunction, induced by experimental biliary ligation (EBL), impairs lymphocytic responsiveness to PHA stimulation in vitro and to cellular antigens in vivo. This suppression appears to be selective for T-cell mechanisms while B-cell-mediated functions remain intact. The purpose of this study was to determine whether coexisting hepatic insufficiency could exert a protective effect on vascularized or nonvascularized allograft survival in the transplanted recipient. Female Wistar-Furth (Rtlw) 225 g rats were assigned randomly to three groups: EBL, sham operation (Sham) and normal control (NC). Fourteen days following operation animals received heterotopic cardiac or skin allografts from Buffalo (Rtlb) donors. Cardiac and skin graft survival was determined daily, rejection was confirmed histologically, and technical failures were omitted from analysis. Allograft survival was expressed as median survival time ± SEM. Serum total bilirubin (mean ± SEM) was significantly elevated at Day 14 in EBL animals compared to Sham and NC groups (15.1 ± 1.0 vs 0.1 ± 0 and 0.2 ± 0.1 mg/dl, respectively, P <0.01). Median cardiac allograft survival time by Probit was 10.6 ± 2.6 vs 5.6 ± 0.7 and 6.0 ± 0.9 days, respectively (P <0.03). Skin graft survival (mean and range) was similar in all groups. These results demonstrate that EBL in the rat suppresses T-cell function and significantly prolongs vascularized allograft survival, but not skin allograft survival across the Rtl histocompatibility barrier. The mechanism whereby coexisting hepatic dysfunction exerts a protective effect on vascularized allograft survival warrants further investigation.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalJournal of Surgical Research
Volume42
Issue number5
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Allografts
Liver
Ligation
Skin
Graft Survival
Hepatic Insufficiency
T-Lymphocytes
Histocompatibility
Buffaloes
Bilirubin
B-Lymphocytes
Antigens
Control Groups
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

The protective effect of hepatic dysfunction on vascularized allograft survival. / Roughneen, Patrick; Didlake, R.; Kumar, S. C.; Kahan, B. D.; Rowlands, B. J.

In: Journal of Surgical Research, Vol. 42, No. 5, 1987, p. 447-453.

Research output: Contribution to journalArticle

Roughneen, Patrick ; Didlake, R. ; Kumar, S. C. ; Kahan, B. D. ; Rowlands, B. J. / The protective effect of hepatic dysfunction on vascularized allograft survival. In: Journal of Surgical Research. 1987 ; Vol. 42, No. 5. pp. 447-453.
@article{4e4164c5f1bb4486b9288a02260539ea,
title = "The protective effect of hepatic dysfunction on vascularized allograft survival",
abstract = "Recent studies have demonstrated that hepatic dysfunction, induced by experimental biliary ligation (EBL), impairs lymphocytic responsiveness to PHA stimulation in vitro and to cellular antigens in vivo. This suppression appears to be selective for T-cell mechanisms while B-cell-mediated functions remain intact. The purpose of this study was to determine whether coexisting hepatic insufficiency could exert a protective effect on vascularized or nonvascularized allograft survival in the transplanted recipient. Female Wistar-Furth (Rtlw) 225 g rats were assigned randomly to three groups: EBL, sham operation (Sham) and normal control (NC). Fourteen days following operation animals received heterotopic cardiac or skin allografts from Buffalo (Rtlb) donors. Cardiac and skin graft survival was determined daily, rejection was confirmed histologically, and technical failures were omitted from analysis. Allograft survival was expressed as median survival time ± SEM. Serum total bilirubin (mean ± SEM) was significantly elevated at Day 14 in EBL animals compared to Sham and NC groups (15.1 ± 1.0 vs 0.1 ± 0 and 0.2 ± 0.1 mg/dl, respectively, P <0.01). Median cardiac allograft survival time by Probit was 10.6 ± 2.6 vs 5.6 ± 0.7 and 6.0 ± 0.9 days, respectively (P <0.03). Skin graft survival (mean and range) was similar in all groups. These results demonstrate that EBL in the rat suppresses T-cell function and significantly prolongs vascularized allograft survival, but not skin allograft survival across the Rtl histocompatibility barrier. The mechanism whereby coexisting hepatic dysfunction exerts a protective effect on vascularized allograft survival warrants further investigation.",
author = "Patrick Roughneen and R. Didlake and Kumar, {S. C.} and Kahan, {B. D.} and Rowlands, {B. J.}",
year = "1987",
doi = "10.1016/0022-4804(87)90017-5",
language = "English (US)",
volume = "42",
pages = "447--453",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - The protective effect of hepatic dysfunction on vascularized allograft survival

AU - Roughneen, Patrick

AU - Didlake, R.

AU - Kumar, S. C.

AU - Kahan, B. D.

AU - Rowlands, B. J.

PY - 1987

Y1 - 1987

N2 - Recent studies have demonstrated that hepatic dysfunction, induced by experimental biliary ligation (EBL), impairs lymphocytic responsiveness to PHA stimulation in vitro and to cellular antigens in vivo. This suppression appears to be selective for T-cell mechanisms while B-cell-mediated functions remain intact. The purpose of this study was to determine whether coexisting hepatic insufficiency could exert a protective effect on vascularized or nonvascularized allograft survival in the transplanted recipient. Female Wistar-Furth (Rtlw) 225 g rats were assigned randomly to three groups: EBL, sham operation (Sham) and normal control (NC). Fourteen days following operation animals received heterotopic cardiac or skin allografts from Buffalo (Rtlb) donors. Cardiac and skin graft survival was determined daily, rejection was confirmed histologically, and technical failures were omitted from analysis. Allograft survival was expressed as median survival time ± SEM. Serum total bilirubin (mean ± SEM) was significantly elevated at Day 14 in EBL animals compared to Sham and NC groups (15.1 ± 1.0 vs 0.1 ± 0 and 0.2 ± 0.1 mg/dl, respectively, P <0.01). Median cardiac allograft survival time by Probit was 10.6 ± 2.6 vs 5.6 ± 0.7 and 6.0 ± 0.9 days, respectively (P <0.03). Skin graft survival (mean and range) was similar in all groups. These results demonstrate that EBL in the rat suppresses T-cell function and significantly prolongs vascularized allograft survival, but not skin allograft survival across the Rtl histocompatibility barrier. The mechanism whereby coexisting hepatic dysfunction exerts a protective effect on vascularized allograft survival warrants further investigation.

AB - Recent studies have demonstrated that hepatic dysfunction, induced by experimental biliary ligation (EBL), impairs lymphocytic responsiveness to PHA stimulation in vitro and to cellular antigens in vivo. This suppression appears to be selective for T-cell mechanisms while B-cell-mediated functions remain intact. The purpose of this study was to determine whether coexisting hepatic insufficiency could exert a protective effect on vascularized or nonvascularized allograft survival in the transplanted recipient. Female Wistar-Furth (Rtlw) 225 g rats were assigned randomly to three groups: EBL, sham operation (Sham) and normal control (NC). Fourteen days following operation animals received heterotopic cardiac or skin allografts from Buffalo (Rtlb) donors. Cardiac and skin graft survival was determined daily, rejection was confirmed histologically, and technical failures were omitted from analysis. Allograft survival was expressed as median survival time ± SEM. Serum total bilirubin (mean ± SEM) was significantly elevated at Day 14 in EBL animals compared to Sham and NC groups (15.1 ± 1.0 vs 0.1 ± 0 and 0.2 ± 0.1 mg/dl, respectively, P <0.01). Median cardiac allograft survival time by Probit was 10.6 ± 2.6 vs 5.6 ± 0.7 and 6.0 ± 0.9 days, respectively (P <0.03). Skin graft survival (mean and range) was similar in all groups. These results demonstrate that EBL in the rat suppresses T-cell function and significantly prolongs vascularized allograft survival, but not skin allograft survival across the Rtl histocompatibility barrier. The mechanism whereby coexisting hepatic dysfunction exerts a protective effect on vascularized allograft survival warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0023202168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023202168&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(87)90017-5

DO - 10.1016/0022-4804(87)90017-5

M3 - Article

VL - 42

SP - 447

EP - 453

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 5

ER -